Showing 4631-4640 of 5771 results for "".
- American Academy of Ophthalmology In-Person Meeting Cancelledhttps://modernod.com/news/american-academy-of-ophthalmology-in-person-meeting-cancelled/2478008/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) has cancelled its in-person annual meeting scheduled to take place in November in Las Vegas. “In light of epidemiological projections, government regulations and public health mandates to prevent the spread of
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Schwind Receives CE Mark Approval for the Schwind ATOS Femtosecondhttps://modernod.com/news/schwind-receives-ce-mark-approval-for-the-schwind-atos-femtosecond/2478006/Schwind eye-tech-solutions announced that it has received CE Mark approval for the Schwind ATOS femtosecond laser. This enables refractive surgeons to offer their patients SmartSight, the latest generation of lenticul
- ImprimisRx: Clinical Study Examines Combination Prescription Eyedropshttps://modernod.com/news/imprimisrx-clinical-study-examines-combination-prescription-eyedrops/2478002/ImprimisRx announced the findings from a randomized contralateral eye study comparing patient outcomes and preferences for a combination therapy with individual eye drop medications after ocular surgery. The prospective study,
- Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-Specific Antibody Therapeutics for Cancer and Retinal Diseaseshttps://modernod.com/news/numab-therapeutics-and-boehringer-ingelheim-enter-into-collaboration-to-develop-multi-specific-antibody-therapeutics-for-cancer-and-retinal-diseases/2478000/Boehringer Ingelheim and Numab Therapeutics announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic
- Vision Expo West 2020 Cancelled; Virtual Offerings Plannedhttps://modernod.com/news/vision-expo-west-2020-cancelled-new-virtual-offerings-planned/2477995/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced the decision to cancel Vision Expo West 2020, scheduled to take place in Las Vegas from September 23-26. “Over the past several months, Reed Exhibitions’ Vision Expo team and The Vision Council worked toget
- LumiThera Closes Series C Round of Financinghttps://modernod.com/news/lumithera-closes-series-c-round-of-financing/2477993/LumiThera announced it has completed its Series C financing. The company raised approximately $14 million to support further commercialization of its Valeda Light Delivery System for the treatment for dry age-related macular degeneration (AMD), to complete its LIGHTS
- CooperVision Encourages Free Registration for Focus on Eye Health National Summithttps://modernod.com/news/coopervision-encourages-free-registration-for-focus-on-eye-health-national-summit/2477992/CooperVision is encouraging the optometry, ophthalmology, vision science and public health communities to participate in the 9th annual “Focus on Eye Health National Summit,” presented by Prevent Blindness on Wednesday, July 15. The summit’s online format and no-cost
- Laboratory Studies Confirm Betadine Antiseptic Products’ Effectiveness Against COVID-19 Virushttps://modernod.com/news/laboratory-studies-confirm-betadine-antiseptic-products-effectiveness-against-covid-19-virus/2477989/Mundipharma announced that laboratory testing at the Duke-NUS Medical School in Singapore has confirmed the effectiveness of its Betadine antiseptic products against the novel coronavirus (SARS-CoV-2). Testing has demonstrated Betadine strong in-vitro virucidal activity, killing 99.99% of